Rainbow Coral Corp., via wholly owned subsidiary Rainbow BioSciences, LLC, markets and develops new medical and research technology innovations through partnerships with biotech developers. Rainbow BioSciences is currently looking to partake in the $142 billion U.S. drug delivery market as it continues partnering talks with a transdermal patch company.
The transdermal delivery market is expected to increase up to $31.5 billion by 2015, and industry experts forecast the growth to continue as its applications extend to include many treatments, including nicotine addiction and Parkinson's disease.
"Personalized medicine is the future," RBCC CEO Patrick Brownstated in the press release. "This is an incredible breakthrough for any patient who doesn't want to take pills or is afraid of needles. The transdermal patch empowers the patient to medicate on their schedule. It is perfect for our growing elderly population."
Transdermal patches are saturated with a specific medicine. Adhered directly to the skin, transdermal patches gradually dispense the medicine to the designated area of the body. The ease of use, reduced side effects, and other benefits, contribute to the growing popularity and application of transdermal patches.
For more information visitwww.RainbowBioSciences.com
Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net